Beyond Supportive Care: Nucleoside Therapy Mechanism and Outcomes in TK2D

"Beyond Supportive Care: Nucleoside Therapy Mechanism and Outcomes in TK2D" examines where supportive care stops and what the first approved therapy offers.

Dr. Hirano asks what supportive care has achieved for Case 1 and where it falls short. Dr. Zolkipli-Cunningham says supportive care has improved quality of life across mitochondrial disease, but it treats symptoms while disease progression continues. Lost motor milestones remain lost, and she wonders whether dedicated treatment could have restored them. In adults, ptosis, a softer voice, and fatigue can threaten employment, bringing a heavy socioeconomic burden.

Dr. Hirano then notes the FDA approval in November 2025 of doxecitine and doxribtimine for TK2D with onset on or before age 12, and asks about the mechanism. Dr. Zolkipli-Cunningham explains that replacing the deficient mitochondrial nucleotide pool could attenuate the pathophysiologic cascade. Pyrimidine deoxynucleosides increase substrate for residual mitochondrial TK2 activity and allow phosphorylation through cytosolic kinases. This restores the deoxynucleotide pool, reduces mitochondrial DNA depletion, and attenuates oxidative phosphorylation impairment. She highlights that the therapy is oral, a major benefit for patients from young age through adulthood. Dr. Hirano adds that the cytosolic pathway involving TK1 supplements residual TK2, so treatment targets the root cause.

Dr. Zolkipli-Cunningham then describes a 2026 paper pooling 104 treated and 114 untreated patients from retrospective studies, prospective open-label studies, and expanded access programs. Survival and motor milestones were primary outcomes. The 30-year restricted mean survival was 29.2 years in treated patients versus 14.4 years in untreated patients. Of treated patients, 75% reacquired lost motor milestones and 25% gained more than four, whereas 80% of untreated patients lost a milestone without expecting to regain it. Dr. Hirano calls this improvement, not mere stabilization, which is unusual.

The next episode in this series, "Dosing Nucleoside Therapy in Early-Onset TK2D and Managing Diarrhea," features the panel applying this therapy to the four-year-old patient, covering dosing, escalation, and management of gastrointestinal effects.